Nolvadex (Tamoxifen Citrate) 100 tabs (20 mg/tab) Dragon Pharma
Nolvadex (Tamoxifen Citrate) is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, Nolvadex is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from Nolvadex therapy.
Nolvadex is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known.
Patients with increased bone pain may require additional analgesics. Patients with soft tissue disease may have sudden increases in the size of preexisting lesions, sometimes associated with marked erythema within and surrounding the lesions and/or the development of new lesions. When they occur, the bone pain or disease flare are seen shortly after starting Nolvadex and generally subside rapidly.
Nolvadex is well tolerated in males with breast cancer. Reports from the literature and case reports suggest that the safety profile of Nolvadex (Tamoxifen Citrate) in males is similar to that seen in women. Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients.